Executive committee
Our executive team is comprised of senior leaders from across the Company. Together, they form a forward-thinking, collaborative, multicultural group of leaders
Dr. Andreas Amrein was appointed Chief Executive Officer of Stallergenes Greer in April 2025.
Dr. Amrein is a seasoned healthcare executive with more than 25 years of leadership and international experience across a variety of therapeutic areas. Prior to joining Stallergenes Greer, he was Managing Director and member of the Global Leadership Team at Advanced Clinical, a leading global contract research organisation. Dr. Amrein previously held positions of increasing responsibility, notably at Novartis, Abbott and Shire Takeda, where he accrued significant expertise in P&L leadership, specialising in commercial expansions, market entries, product launches, transformations, acquisitions, and integrations.
Dr. Amrein is Swiss and holds a PhD in Health Economics, Evidence Based Medicine and Quality of Life for Rare Diseases from the University of Southern Queensland (Australia), an MBA from INSEAD (France) and a Master of Physics from ETH Zurich (Switzerland).
Valérie Benhamou has more than 25 years of experience in the life science field both in pharmaceutical industry and law firms. Valérie joined Stallergenes Greer in 2017 from Abbott, where she was Senior Legal Counsel for France, Benelux and Africa.
Prior to Abbott, Valérie Benhamou served as Senior counsel for Bristol-Myers Squibb. Earlier in her career, she practiced at law firms and focused on healthcare matters. Valerie holds a master’s degree in Private law and a postgraduate diploma in Intellectual Property law from the University of Paris II. She has been a member of the Paris Bar since 1999.
Mr. Chapuis brings over two decades of international experience in the pharmaceutical and biotech sectors, with deep expertise in global commercial strategy, product launches, geographic expansion, cross-functional leadership, and digital transformation.
Prior to joining Stallergenes Greer, he successfully held senior leadership roles in global commercial and marketing functions at Centogene, Santhera, Shire & Takeda.
Mr. Chapuis holds executive education credentials in leadership and Digital Transformation in Healthcare from INSEAD and Columbia Business School, as well as a Master's degree in Marketing, Sales, and Biotechnology from Université Grenoble Alpes (France).
Dr Babette Güldenpfennig has more than two decades of experience in life sciences areas including licensing, strategic business development and intellectual property.
She previously served as Global Head of Licensing for the Diagnostic Division at F. Hoffman - La Roche Ltd, co-founding and leading the Licensing and IP functions at Kuros Biosurgery, now Kuros Bioscience, and most recently, executive roles at Sintetica SA and TargImmune Therapeutics AG.
Dr Güldenpfennig holds a PhD in Chemistry from ETH Zurich and a Master of Science in Chemistry from the University of Tübingen.
Nicola Lamacchia joined Stallergenes Greer in March 2017 as Head of Finance for Europe and International with a long-standing experience as business partner in biotech manufacturing and commercial management.
Previously, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company’s growth and expansion. He spent over a decade at Merck Serono in senior finance roles across country, regional, and divisional levels, including Head of Divisional Controlling for the Neurology, Fertility and Endocrinology business, Head of Commercial Europe Finance, Global Biotech Manufacturing Controller, Finance and Logistic Director.
Nicola Lamacchia holds a Master’s Degree in Business and Economics from the Bocconi University in Milan, and a Business and Leadership Program MBA from MIT-Sloan.
Tibor Nemes has a proven track record in the biotech and pharmaceutical industry in both Europe and in the United States. He has held leadership roles in engineering, process development, quality assurance and the manufacturing of biologics, solids, and sterile dosage forms.
Tibor joined Stallergenes Greer in 2016 as Global Head of Technical Operations before taking over as Head of the Americas in May 2018.
He previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A where he headed Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.
Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at pharmaceutical and biotechnology companies including Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.
Dominique Pezziardi joined Stallergenes Greer in 2012 and currently serves as Executive Vice President for Western and Southern Europe, and President of Stallergenes SAS.
He held roles of increasing responsibility in the pharmaceutical industry, holding positions in sales, marketing and strategy at local, regional and global levels.
Prior to joining Stallergenes Greer, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, orphan diseases, cardiology and medical devices, within pharmaceutical companies including Ciba, Sanofi and Merck Serono.
He successfully managed global product launches, life cycle development plans, mature franchises relaunches, alliances with strategic partners or more recently, corporate strategy development.
Dominique Pezziardi graduated from a business school in Bordeaux, France, and trained in pharmaco-economy in Milano, Italy.
Dr Elena Rizova brings 22 years of international experience in the pharmaceutical industry.
She has gained extensive expertise in drug development and the launch of new entities in dermatology, immunology, oncology, the central nervous system and infectious and cardiovascular diseases. She has significant leadership experience and has led complex cross-country matrix teams in medical, clinical, regulatory affairs, pharmacovigilance as well as in medical information and communication.
In her most recent role as VP and Head of the Intercontinental Region, she oversaw Biogen’s medical teams and neuroscience portfolio based in Switzerland. She previously served as Global Head of Medical Affairs for Dermatology at Sanofi Genzyme based in the US. Prior to joining Sanofi Genzyme, she held several leadership roles at Johnson & Johnson Innovation Asia Pacific, Janssen based in Europe and Asia , 3M Pharmaceutical based in Europe and Galderma based in France.
Dr Elena Rizova is a medical doctor and a board-certified dermatologist with a PhD in immunology.
Dr Julien Storaï joined Stallergenes Greer as Senior Vice President Pharmaceutical Operations in 2023.
With more than 20 years of experience in the pharmaceutical industry, Dr Julien Storaï was previously Chief Technical Officer at OM Pharma in Geneva (Switzerland), where he oversaw global industrial activities and was responsible for assuring the company’s internal and external long-term industrial strategy. He also held site head and manufacturing positions at Vifor Pharma and began his professional career at Sanofi in Vaccine Industrial Development.
Dr Julien Storaï holds a PhD in Industrial Microbiology, Biochemistry Engineer INSA (France), an MBA EM Lyon (France) and is certified Black Belt Six Sigma.
Jérôme Tilly joined Stallergenes Greer in 2014 as Senior Vice President Human Resources, Europe and International.
He previously worked at Sogefi, an Italian automotive supplier, where he served as Vice President Human Resources. Throughout his career, he held positions of increasing responsibility and gained in-depth knowledge of human resources at automotive, airport ground handling and media companies.
Jérôme Tilly holds a master's degree in business administration, employment law and Human Resources from Paris Dauphine University, France
Petr Tor joined Stallergenes Greer with significant international experience in the pharmaceutical industry, holding positions in finance, marketing and sales at local and regional levels.
He gained his expertise in several therapeutic fields including asthma, cardio, diabetes, glaucom, antibiotics, antifungals and HIV during his 16 years at Merck & Co. MSD in Europe).
He joined Stallergenes Greer in 2010 as General Manager for the Czech and Slovak subsidiary and, since 2014, has held commercial responsibilities for various regions with growing scope and complexity in Europe, Middle East and Africa.
Petr Tor holds a degree in Chemistry from the Institute of Chemical Technology in Prague and a diploma in Accounting and Finance at MBA Rochester Institute of Technology, New York US Business School in Prague.